

UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

MYLAN PHARMACEUTICALS INC.
and PFIZER INC.,
Petitioners,

v.

SANOFI-AVENTIS DEUTSCHLAND GMBH,
Patent Owner

Case IPR2018-01676¹
U.S. Patent No. 8,603,044

PATENT OWNER'S SUR-REPLY

¹ Pfizer Inc., who filed a petition in IPR2019-00978, has been joined as petitioner in this proceeding.

TABLE OF CONTENTS

Page

I.	GROUND 1 DOES NOT RENDER THE CHALLENGED CLAIMS OBVIOUS.....	1
A.	Steenfeldt-Jensen Does Not Suggest a Threaded Driver Tube.....	1
B.	Even If Steenfeldt-Jensen Did Suggest a Threaded Driver Tube With Respect to Its First Embodiment, It Would Not Apply to the Fifth Embodiment.....	1
C.	Even If Steenfeldt-Jensen Suggested a Threaded Driver Tube With Respect to Its First Embodiment, A POSA Would Not Be Motivated to Make Petitioners’ Modification to the Fifth Embodiment	3
1.	A High Injection Force Would Dissuade a POSA From Petitioners’ Modification	4
2.	Petitioners Argue that Their Modification is Obvious Solely On the Basis of Reasonable Expectation of Success	4
3.	Sanofi Presented Non-Obviousness Arguments Beyond the Friction Collar Model.....	5
D.	Dr. Slocum’s Models Are Not Flawed.....	5
1.	There is no Bias.....	6
2.	The Analytical Model Tests Total Change in Friction	7
3.	The Models Are Not Designed to Fail.....	8
E.	Steenfeldt-Jensen Does Not Teach or Suggest an Internally Threaded Driver Tube in the Form of an Integrated Nut Member at Column 3, Lines 41-47	9
1.	Steenfeldt-Jensen Does Not Teach a Nut Member Integrally With a Driver Tube.....	10

2.	Steenfeldt-Jensen Does Not Suggest an Nut Member Integrally Formed With a Driver Tube	11
F.	The Board Should Reject Petitioners’ New Argument that Steenfeldt-Jensen Suggests a Threaded Driver Tube Because of Disclosures in Giambattista.....	12
II.	GROUND 2 DOES NOT RENDER THE CHALLENGED CLAIMS OBVIOUS.....	13
A.	A POSA Would Not Be Motivated To Combine Møller’s First and Second Embodiments	14
B.	Møller’s First and Second Embodiments Are Not Structurally or Functionally Equivalent	16
C.	Møller And Steenfeldt-Jensen Do Not Render Obvious A Dose Dial Sleeve With Grooves On Its Outer Surface	17
D.	Møller and Steenfeldt-Jensen Do Not Render Obvious A Clicker With A Flexible Arm And Splines.....	18
III.	CONCLUSION.....	20

TABLE OF AUTHORITIES

	Page(s)
Cases	
<i>In re Gordon</i> , 733 F.2d 900	5
<i>Integra Lifesciences I, Ltd. v. Merck KGaA</i> , 496 F.3d 1334 (Fed. Cir. 2007).....	6
<i>Intelligent Bio-Systems, Inc. v. Illumina Cambridge Ltd.</i> , 821 F.3d 1359 (Fed. Cir. 2016).....	5, 14, 19
<i>KSR Intern. Co. v. Teleflex, Inc.</i> , 550 U.S. 398 (2007).....	19
<i>Personal Web Techs., LLC v. Apple, Inc.</i> , 848 F.3d 987 (Fed. Cir. 2017).....	14
<i>Plas-Pak Indus. v. Sulzer Mixpac AG</i> 600 F. App'x 755 (Fed. Cir. 2015)	5
Statutes and Regulations	
35 U.S.C. § 24.....	7
35 U.S.C. §316(e)	17
37 CFR § 42.24(a)(1)(i)	23
37 CFR § 42.6(a)(2)(ii).....	23
37 CFR § 42.8	23

EXHIBIT LIST

Exhibit #	Description
2001	Press Release, “Mylan Enhances Partnership with Biocon through Strategic Collaboration for Insulin Products”, Feb. 13, 2013 (PR Newswire), available at http://newsroom.mylan.com/press-releases?item=122834
2002	Press Release, “Mylan Commences Phase III Clinical Trials for its Generic Version of Advair Diskus® and Insulin Analog to Lantus®”, Sept. 16, 2014 (PR Newswire), available at http://newsroom.mylan.com/press-releases?item=123251
2003	Press Release, “Mylan and Biocon Present Clinical Data on Insulin Glargine at the American Diabetes Association’s 77th Scientific Sessions”, June 10, 2017 (PR Newswire), available at http://newsroom.mylan.com/2017-06-10-Mylan-and-Biocon-Present-Clinical-Data-on-Insulin-Glargine-at-the-American-Diabetes-Associations-77th-Scientific-Sessions
2004	Complaint for Patent Infringement, <i>Sanofi-Aventis U.S. LLC, Sanofi-Aventis Deutschland GmbH v. Eli Lilly and Company</i> , C.A. No. 1-14-cv-00113-RGA (D. Del), Dkt. No. 1
2005	Complaint for Patent Infringement, <i>Sanofi-Aventis U.S. LLC, Sanofi-Aventis Deutschland GmbH, and Sanofi Winthrop Industrie v. Merck Sharp & Dohme Corp.</i> , C.A. No. 1-16-cv-00812-RGA (D. Del), Dkt. No. 1
2006	Stipulation and Proposed Order, <i>Sanofi-Aventis U.S. LLC v. Mylan, N.V.</i> , Civil Action No. 17-9105-SRC-SLW (D.N.J. Feb 5, 2018), Dkt. No. 45
2007	Complaint for Patent Infringement, <i>Sanofi-Aventis U.S. LLC et al. v. Mylan N.V. et al.</i> , Case No. 2:17-cv-09105-SRC-CLW (D.N.J. Oct. 24, 2017), Dkt. No. 1
2008	Excerpts from Defendants’ Invalidity Contentions, dated Jan. 25, 2018, <i>Sanofi-Aventis U.S. LLC et al. v. Mylan N.V. et al.</i> , Case No. 2:17-cv-09105-SRC-CLW (D.N.J.)
2009	Excerpts from Mylan GMBH’s Amended Invalidity Contentions, dated April 25, 2018, <i>Sanofi-Aventis U.S. LLC et al. v. Mylan N.V. et al.</i> , Case No. 2:17-cv-09105-SRC-CLW (D.N.J.)
2010	Excerpts from Mylan GMBH’s Exhibit C to Amended Invalidity

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.